Dr. Christopher Lemmon, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 113
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD494770
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
- West Chester Hospital West Chester, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 113
- Services billed
- 347
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 80 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 67 | 36 |
| Established patient office or other outpatient visit, 20-29 minutes | 34 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Pittsburgh, PA | 72 |
| Prochlorperazine Maleate Other prescribers in Pittsburgh, PA | 56 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Pittsburgh, PA | 28 |
| Tagrisso (osimertinib mesylate) | 24 |
| Duloxetine Hcl Other prescribers in Pittsburgh, PA | 22 |
| Oxycodone Hcl Other prescribers in Pittsburgh, PA | 20 |
| Olanzapine Other prescribers in Pittsburgh, PA | 20 |
| Prednisone Other prescribers in Pittsburgh, PA | 13 |
| Levothyroxine Sodium Other prescribers in Pittsburgh, PA | 12 |
| Gabapentin Other prescribers in Pittsburgh, PA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $105 in total to this clinician.
| Merck Sharp & Dohme LLC | $70.00 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $34.56 |
| Food and Beverage | $105 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $225,615 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Tr…
Merck Sharp & Dohme LLC - A randomized, double-blind, placebo-controlled phase 3 study to evalua
GlaxoSmithKline, LLC. - BNT113-01
BioNTech SE - A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Recruiting · NCT06064877 - A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib …
Merck Sharp & Dohme LLC - A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.